• Journey Medical Corp DERM.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of four analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -11 cents to -5 cents per share.

• Revenue rose 21.5% to $15.96 million from a year ago; analysts expected $15.95 million.

• Journey Medical Corp's reported EPS for the quarter was a loss of 8 cents​.

• The company reported a quarterly loss of $2.23 million.

• Journey Medical Corp shares had risen by 6.8% this quarter and lost 35.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 158.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Journey Medical Corp is $13.00, about 60.1% above its last closing price of $5.19

This summary was machine generated from LSEG data May 13 at 09:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)